| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.0031 | 1 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.0029 | 1 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | -0.0017 | 1 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.0017 | 1 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.0018 | 1 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0017 | 1 |